Novel cleavable cell-penetrating peptide-drug conjugates: Synthesis and characterization

Journal of Peptide Science

Volumn 20, Issue 5, 2014, Pages 323-333

  Lelle, Marco ^a   Frick, Stefanie U ^a,b   Steinbrink, Kerstin ^b   Peneva, Kalina ^a  

^a MAX PLANCK INSTITUTE FOR POLYMER RESEARCH   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

anthracyclines; antitumor agents; drug delivery; peptides; synthesis

Indexed keywords

ALIPHATIC KETONE; ANTHRACYCLINE; CELL PENETRATING PEPTIDE; CYSTEINE; DAUNOSAMINE; DOXORUBICIN; GLUTATHIONE; LIPOSOME; MERCAPTAMINE; OXIME; POLYARGININE; ANTINEOPLASTIC AGENT;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ENCAPSULATION; CELL PROLIFERATION ASSAY; CELL VIABILITY ASSAY; CELLULAR DISTRIBUTION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DISULFIDE BOND; DNA BINDING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; FLOW CYTOMETRY; FLUORESCENCE SPECTROSCOPY; HT 29 CELL LINE; HUMAN; HUMAN CELL; IC 50; INTERNALIZATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MCF 7 CELL LINE; PH; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN SECONDARY STRUCTURE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; HT29 CELLS; HUMANS; MCF-7 CELLS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84899648388     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2617     Document Type: Article

References (48)

1. Wagstaff KM, Jans DA,. Protein transduction: cell penetrating peptides and their therapeutic applications. Curr. Med. Chem. 2006; 13: 1371-1387.
2. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y,. Arginine-rich peptides-an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 2001; 276: 5836-5840.
3. Mager I, Eiriksdottir E, Langel K, Andaloussi SEL, Langel U, Assessing the uptake kinetics and internalization mechanisms of cell-penetrating peptides using a quenched fluorescence assay. BBA-Biomembranes 2010; 1798: 338-343.
4. Dubikovskaya EA, Thorne SH, Pillow TH, Contag CH, Wender PA,. Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc. Natl. Acad. Sci. U. S. A. 2008; 105: 12128-12133.
5. Muratovska A, Eccles MR,. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 2004; 558: 63-68. (Pubitemid 38167411)
6. Nguyen J, Xie XL, Neu M, Dumitrascu R, Reul R, Sitterberg J, Bakowsky U, Schermuly R, Fink L, Schmehl T, Gessler T, Seeger W, Kissel T,. Effects of cell-penetrating peptides and pegylation on transfection efficiency of polyethylenimine in mouse lungs. J. Gene Med. 2008; 10: 1236-1246.
7. Sajti CL, Barchanski A, Wagener P, Klein S, Barcikowski S,. Delay time and concentration effects during bioconjugation of nanosecond laser-generated nanoparticles in a liquid flow. J. Phys. Chem. C 2011; 115: 5094-5101.
8. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF,. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999; 285: 1569-1572. (Pubitemid 29420581)
9. Brasseur R, Divita G,. Happy birthday cell penetrating peptides: already 20 years. BBA-Biomembranes 2010; 1798: 2177-2181.
10. Hallbrink M, Oehlke J, Papsdorf G, Bienert M,. Uptake of cell-penetrating peptides is dependent on peptide-to-cell ratio rather than on peptide concentration. BBA-Biomembranes 2004; 1667: 222-228. (Pubitemid 39576087)
11. Alves ID, Jiao CY, Aubry S, Aussedat B, Burlina F, Chassaing G, Sagan S,. Cell biology meets biophysics to unveil the different mechanisms of penetration internalization in cells. BBA-Biomembranes 2010; 1798: 2231-2239.
12. Deshayes S, Konate K, Aldrian G, Crombez L, Heitz F, Divita G,. Structural polymorphism of non-covalent peptide-based delivery systems: highway to cellular uptake. BBA-Biomembranes 2010; 1798: 2304-2314.
13. Hirose H, Takeuchi T, Osakada H, Pujals S, Katayama S, Nakase I, Kobayashi S, Haraguchi T, Futaki S,. Transient focal membrane deformation induced by arginine-rich peptides leads to their direct penetration into cells. Mol. Ther. 2012; 20: 984-993.
14. Jones AT, Sayers EJ,. Cell entry of cell penetrating peptides: tales of tails wagging dogs. J. Controlled Release 2012; 161: 582-591.
15. Milletti F,. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov. Today 2012; 17: 850-860.
16. Fernandez-Carneado J, Kogan MJ, Pujals S, Giralt E,. Amphipathic peptides and drug delivery. Biopolymers 2004; 76: 196-203. (Pubitemid 38529434)
17. Sadler K, Eom KD, Yang JL, Dimitrova Y, Tam JP,. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry (Mosc.) 2002; 41: 14150-14157. (Pubitemid 35403333)
18. Martin I, Teixido M, Giralt E,. Design, synthesis and characterization of a new anionic cell-penetrating peptide: SAP(E). ChemBioChem 2011; 12: 896-903.
19. Weiss RB,. The anthracyclines-will we ever find a better doxorubicin. Semin. Oncol. 1992; 19: 670-686. (Pubitemid 23004844)
20. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L,. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004; 56: 185-229. (Pubitemid 38720829)
21. Wang F, Wang YC, Dou S, Xiong MH, Sun TM, Wang J,. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. Acs Nano 2011; 5: 3679-3692.
22. Riganti C, Voena C, Kopecka J, Corsetto PA, Montorfano G, Enrico E, Costamagna C, Rizzo AM, Ghigo D, Bosia A,. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol. Pharm. 2011; 8: 683-700.
23. Greenfield RS, Kaneko T, Daues A, Edson MA, Fitzgerald KA, Olech LJ, Grattan JA, Spitalny GL, Braslawsky GR,. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Cancer Res. 1990; 50: 6600-6607. (Pubitemid 20348786)
24. Willner D, Trail PA, Hofstead SJ, King HD, Lasch SJ, Braslawsky GR, Greenfield RS, Kaneko T, Firestone RA,. (6-Maleimidocaproyl)hydrazone of doxorubicin-a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjugate Chem. 1993; 4: 521-527. (Pubitemid 2018209)
25. Kratz F, Beyer U, Roth T, Tarasova N, Collery P, Lechenault F, Cazabat A, Schumacher P, Unger C, Falken U,. Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy. J. Pharm. Sci. 1998; 87: 338-346. (Pubitemid 28204588)
26. Duncan R, Gaspar R,. Nanomedicine(s) under the microscope. Mol. Pharm. 2011; 8: 2101-2141.
27. Schlage P, Mezo G, Orban E, Bosze S, Manea M,. Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect. J. Controlled Release 2011; 156: 170-178.
28. Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K,. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjugate Chem. 2005; 16: 122-130. (Pubitemid 40129685)
29. Szabo I, Manea M, Orban E, Antal C, Bosze S, Szabo R, Tejeda M, Gaal D, Kapuvari B, Przybylski M, Hudecz F, Mezo G,. Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug. Bioconjugate Chem. 2009; 20: 656-665.
30. Kalia J, Raines RT,. Hydrolytic stability of hydrazones and oximes. Angew. Chem. Int. Ed. 2008; 47: 7523-7526.
31. Kratz F,. Drug conjugates with albumin and transferrin. Expert Opin. Ther. Pat. 2002; 12: 433-439. (Pubitemid 34223902)
32. Schulz A, Adermann K, Eulitz M, Feller SM, Kardinal C,. Preparation of disulfide-bonded polypeptide heterodimers by titration of thio-activated peptides with thiol-containing peptides. Tetrahedron 2000; 56: 3889-3891. (Pubitemid 30422390)
33. Sigler GF, Ed.: U. S. Patent, US 4709037, 1987.
34. Webb RR, Kaneko T,. Synthesis of 1-(aminooxy)-4-[(3-nitro-2-pyridyl) dithio]butane and 1-(aminooxy)-4-[(3-nitro-2-pyridyl)dithio]but-2-ene, novel heterobifunctional cross-linking reagents. Bioconjugate Chem. 1990; 1: 96-99.
35. Rucker AL, Creamer TP,. Polyproline II helical structure in protein unfolded states: lysine peptides revisited. Protein Sci. 2002; 11: 980-985. (Pubitemid 34241306)
36. Pujals S, Giralt E, Proline-rich, amphipathic cell-penetrating peptides. Adv. Drug Del. Rev. 2008; 60: 473-484.
37. Meister A, Anderson ME,. Glutathione. Annu. Rev. Biochem. 1983; 52: 711-760. (Pubitemid 13030692)
38. Balendiran GK, Dabur R, Fraser D,. The role of glutathione in cancer. Cell Biochem. Funct. 2004; 22: 343-352. (Pubitemid 39518098)
39. Orban E, Mezo G, Schlage P, Csik G, Kulic Z, Ansorge P, Fellinger E, Moller H, Manea M,. In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites. Amino Acids 2011; 41: 469-483.
40. SM Deneke, BL Fanburg, Regulation of cellular glutathione. Am. J. Physiol. 1989; 257: L163-L173.
41. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R,. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 2007; 8: 848-866. (Pubitemid 46971632)
42. Siegfried JM, Burke TG, Tritton TR,. Cellular transport of anthracyclines by passive diffusion: implications for drug resistance. Biochem. Pharmacol. 1985; 34: 593-598. (Pubitemid 15110172)
43. Perfetto SP, Chattopadhyay PK, Lamoreaux L, Nguyen R, Ambrozak D, Koup RA, Roederer M,. Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. J. Immunol. Methods 2006; 313: 199-208.
44. Cummings J, Anderson L, Willmott N, Smyth JF,. The molecular pharmacology of doxorubicin in vivo. Eur. J. Cancer 1991; 27: 532-535.
45. Nadas J, Sun DX,. Anthracyclines as effective anticancer drugs. Expert Opin. Drug Discov. 2006; 1: 549-568.
46. Tuennemann G, Ter-Avetisyan G, Martin RM, Stoeckl M, Herrmann A, Cardoso C,. Live-cell analysis of cell penetration ability and toxicity of oligo-arginines. J. Pept. Sci. 2008; 14: 469-476. (Pubitemid 351540908)
47. Pelkmans L, Helenius A,. Endocytosis via caveolae. Traffic 2002; 3: 311-320 (Pubitemid 34461041)
48. Nakase I, Konishi Y, Ueda M, Saji H, Futaki S,. Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo. J. Controlled Release 2012; 159: 181-188.